Tatalaksana Non-Acetaminophen Induced Acute Liver Failure Dengan Menggunakan N-acetylcysteine

  • Mia Putri Sahara UNRAM

Abstract

Gagal hati akut adalah suatu kondisi di mana terjadi disfungsi hati akut. Ada dua jenis gagal hati akut, yaitu gagal hati akut yang diinduksi asetaminofen dan gagal hati akut yang diinduksi non-asetaminofen. Gagal hati akut memiliki angka kejadian 1-6 kasus per 1 juta orang setiap tahunnya di negara maju, sedangkan untuk negara berkembang penilaiannya diperkirakan angka kejadiannya lebih besar karena memiliki angka kejadian hepatitis yang tinggi, di Amerika diperkirakan sebesar sebanyak 2500 kasus gagal hati akut per tahun. Sampai saat ini, tidak ada pengobatan yang efektif untuk gagal hati akut yang tidak disebabkan oleh asetaminofen selain transplantasi hati. Berdasarkan hasil analisis penelitian yang dilakukan, pengobatan terapeutik N-acetylcysteine ????(NAC) pada gagal hati akut yang diinduksi non-asetamin terbuka dapat menjanjikan.

References

1. Weiler N, Schlotmann A, Schnitzbauer AA, Zeuzem S, Welker MW. The epidemiology of acute liver failure: Results of a population-based study including 25 million state-insured individuals. Dtsch Arztebl Int. 2020;117(4):43– 50.
2. Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study. Saudi J Gastroenterol. 2017;23(3):169–75.
3. Fontana RJ, Engle RE, Gottfried M, Hammed B, Hanje J, Durkalski V, et al. Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury. Clin Transl Gastroenterol. 2020;11(11):e00273.
4. Chughlay MF, Kramer N, Spearman CW, Werfalli M, Cohen K. N- acetylcysteine for non-paracetamol drug-induced liver injury: A systematic review. Br J Clin Pharmacol. 2016;81(6):1021–9.
5. Jaeschke H, Akakpo JY, Umbaugh DS, Ramachandran A. Novel Therapeutic Approaches Against Acetaminophen-induced Liver

Injury and Acute Liver Failure. Toxicol Sci. 2020;174(2):159–67.
6. Hu J, Zhang Q, Ren X, Sun Z, Quan
Q. Efficacy and safety of acetylcysteine in “non- acetaminophen” acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2015;39(5):594–9.
7. Yan M, Huo Y, Yin S, Hu H. Mechanisms of acetaminophen- induced liver injury and its implications for therapeutic interventions. Redox Biol. 2018;17(March):274–83.
8. Acute B. N-acetylcysteine for acute liver failure not caused by paracetamol overdose. 2021;1–4.
9. Mendizabal M, Silva MO. Liver transplantation in acute liver failure: A challenging scenario. World J Gastroenterol. 2016;22(4):1523–31.
10. Akakpo JY, Ramachandran A, Kandel SE, Ni H, Kumer SC, Rumack BH, et al. 4- Methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocyte. Physiol Behav. 2018;176(3):139–48.
11. Akakpo JY, Ramachandran A, Duan L, Schaich MA, Jaeschke MW, Freudenthal BD, et al. Delayed Treatment with 4-
Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n- Terminal Kinase. Toxicol Sci.
2019;170(1):57–68.
12. Walayat S, Shoaib H, Asghar M,
Kim M, Dhillon S. Role of N- acetylcysteine in non- acetaminophen-related acute liver failure: An updated meta-analysis and systematic review. Ann Gastroenterol. 2021;34(2):235–40.
Published
2022-12-30
Section
Literature Review